Join us on 12-15-2022 for a live seminar about RNA SEQ
Join us on 12-15-2022 for a live seminar about RNA SEQ
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. We collaborate with our partners to design the best therapeutic campaigns and engagements to meet your pipeline goals. If you are ready to connect with our team in real time to discuss your therapeutic biologics discovery needs, click the button below to schedule a time with us.
If you’d rather hear from someone over email, please complete our form and we will be in touch shortly.
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.
Complete our form and someone will be in touch shortly.
Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat annual fee through Alloy’s Innovation Subscriptions offering. Read our recent announcements below to learn how we collaborate with our partners.
Learn how we partner with the global drug discovery community to help them advance the best drug candidates.
Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.
G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy’s DeepImmune™ Antibody Discovery service builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.
asdf
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.
Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.
G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.
I’d like more material about Keyway TCR Discovery
Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:
1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target
Upon filling out this form, you will receive an email with a link to the webinar recording.
